Purpose: Patients with priapism often develop permanent erectile dysfunction and personal sexual distress. This report is intended to help educate the public by reviewing the varied definitions and classifications of priapism and limited literature reports of pathophysiology, diagnosis and treatment outcomes of priapism. The AUA priapism guidelines committee is responsible for creating consensus as to appropriate individual patient management of priapism by physicians.
Introduction
The AFUD Sexual Function Health Council, under the auspices of Tom Lue and John Mulcahy cochairs, voted to organize a Thought Leader Panel for educating the public on the Evaluation and Management of Priapism. There were several motivations for convening this Thought Leader Panel on Priapism. During Council discussion, it became apparent that despite the recent explosion of laboratory and clinical research data concerning erectile physiology and safe and effective erectile dysfunction therapies, there has been limited understanding of the pathophysiology, diagnosis and timely treatment of priapism as well as limited public education about the condition. There are at present no consensus or guidelines as to how to manage priapism in individual patients. There has been limited multi-institutional clinical outcome research in priapism. The treatment of patients with priapism by primary care physicians and urologists has been varied and often appeared at odds with the clinical situation. Many patients with priapism priapism in individual patients. There has been limited multi-institutional clinical outcome research in priapism. Patients treated for priapism have developed permanent and irreversible erectile dysfunction with associated adverse destructive psychosocial consequences. It was hoped that this Thought Leader Panel would lead to timely discussion of the relevant issues of priapism concerning nomenclature and classification, while creating a vehicle for educating the public on its suggested diagnosis and treatment. The AUA priapism guidelines committee has taken the role of developing appropriate physician guidelines for management of patients with priapism. At the meeting, there were selected presentations on case reports of patients with priapism including interviews revealing the associated distress and devastating psychosocial consequences. William Steers discussed the pathophysiology of ischemic priapism, Irwin Goldstein, the diagnosis and treatment of ischemic priapism and Tom Lue, the pathophysiology, diagnosis and treatment of nonischemic priapism.
Methods
Ray Rosen, the Panel moderator, introduced the meeting format. This included structured group discussion and consensus-voting, according to a strict mathematical formula. Criteria for diagnostic decision-making were evaluated by means of a modified Delphi method. The approach, referred to as the 'Rand Method' for medical decision-making and technology assessment, synthesizes the opinions of thought leaders. The technique is designed to assess the 'appropriateness' of use of clinical procedures or diagnostic decision-making. By drawing on the knowledge and experience of the thought leaders at the time of the voting, the process provided detailed, cost-effective and timely 'appropriateness' for a broad range of situations. As it concerns the Thought Leader Panel on Priapism, the major problems with the meeting were the limitation of currently available data concerning the medical condition of priapism and the subjective nature of the group decision-making process. Throughout the process, panel members communicated freely.
Results
The following represented the panel agreements on definition and classification of priapism.
I. Definition
Priapism is a pathological condition of a penile erection that persists beyond or is unrelated to sexual stimulation. Priapism is an important medical condition that requires evaluation and may require emergency management. The panel recommended the following management scheme for treatment of priapism (Figure 1 ).
IV. Management 1. Initial management
History (medical, sexual) Physical Figure 1 Step care treatment for the management of priapism. Clinical outcome in terms of maintenance of premorbid erectile function is dependent upon the duration of the priapism. As in all ischemic compartment conditions, rapid intervention is a necessity. First line treatments (aspiration, irrigation) for ischemic priapism of more than 4 h duration are highly recommended before any surgical treatment. First line treatments initiated beyond 72 h may have benefits in relieving the unwanted erection and associated pain, but have little documented benefit in terms of potency preservation.
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Choices for management (for sickle cell patient)
Intravenous hydration and parental narcotic analgesia while preparing for aspiration and irrigation Supplemental oxygen Exchange transfusion. 5. Outcome (A) Complete resolution (full detumescence, no pain)
Instructions provided to patient:
Follow-up highly recommended.
Pain management as indicated. Follow-up with a Urologist highly recommended.
Pain management as indicated. Acetaminophen with a mild oral narcotic codeine or hydrocodone for no more than 3 days. (B) Partial resolution (post ischemic edema, persistent partial erection, persistent pain).
In-patient observation recommended. Interval physical examination of penis and=or Interval assessment of corporal blood flow status by corporal aspirate (visual inspection or corporal blood gas) or penile duplex Doppler ultrasound.
Adrenergic agonists may be administered (i.c. and oral) on an interval basis to induce complete detumescence. (C) No resolution: confirm no resolution by assessment of corporal blood flow status by corporal aspirate (visual inspection or corporal blood gas) or penile duplex Doppler ultrasound. Advance stepcare management to surgical shunt. Repeated first line interventions over several hours are the rule rather than the exception.
The decision to perform a shunt procedure is at the discretion of the urologist taking into account such factors as duration of the priapism, age, other medical risk factors. The literature is insufficient to support the use of shunts in prepubertal children.
Treatments initiated beyond 72 h may have benefits in relieving the unwanted erection and associated pain, but have little documented benefit in terms of potency preservation.
Conclusions
The AFUD Thought Leader Panel of Priapism addressed pertinent issues concerning the role of urologist, primary care providers and other health care professionals in the education and management of men with priapism. The panel recommended the adoption of definitions and classifications of priapism to shed light on this problem. The panel recommended a rational management algorithm for the assessment and treatment of priapism to be available for public education. The panel awaits the conclusions of the AUA priapism guidelines committee on this topic. The panel recommended that the cornerstone of initial assessment should include a careful clinical history, a focused physical examination and selected laboratory and=or radiologic tests. The panel recommended that specific criteria and clinical profiles requiring specialist referral should be identified. The panel recommended that patient (and partner) needs and education concerning priapism should be addressed prior to therapeutic intervention. Treatment goals to be discussed include management of the priapism with concomitant prevention of permanent and irreversible erectile dysfunction and associated psychosocial consequences. The panel recommended that when specific therapies for priapism are required, a stepcare treatment approach based upon reversibility and invasiveness should be followed. The panel calls for research to expand our understanding of the prevalence and diagnosis of priapism. Critical areas to be addressed include the multiple pathophysiologies of priapism as well as multi-institutional trials to objectively assess safety and efficacy in the various treatment modalities.
